NCT-0563-3654

A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecanand Pembrolizumab Versus Treatment of Physicians Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy

This research study is looking at a new treatment for triple-negative breast cancer. The new treatment being studied in this trial is a combination of two drugs: sacituzumab govitecan and pembrolizumab. Sacituzumab govitecan is a type of drug called an antibody-drug conjugate (ADC). ADCs are made up of an antibody that is linked to a chemotherapy drug. The antibody helps the ADC target cancer cells, and the chemotherapy drug kills the cancer cells. Pembrolizumab is a type of drug called a checkpoint inhibitor. Checkpoint inhibitors help the immune system recognize and attack cancer cells. The goal of the trial is to see if the new treatment is more effective and safer than the standard treatment at improving survival rates and reducing the risk of cancer recurrence.

Triple-Negative: It is a type of breast cancer in which cells do not have estrogen receptors (ER), progesterone receptors (PR), and HER-2 receptors.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT05633654

NCT-0563-3654

Clinical Trial Site: Sinai

To see all available clinical trials click here.